Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141349 · ClinicalTrials.gov registry record · Phase 2
Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT00141349 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 300 participants.
The verdict
NCT00141349, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is 4 weeks.
Interventions
- DRUG UK-369,003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141349
The ClinicalTrials.gov registry entry for NCT00141349 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UK-369,003 is the first listed.
NCT00141349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00141349 about?
NCT00141349 is a clinical study titled "Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction". To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is 4 weeks.
What is the current status of trial NCT00141349?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2005-02. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00141349?
The interventions under investigation include: UK-369,003 (DRUG).
Who is sponsoring clinical trial NCT00141349?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.